Next Article in Journal
Five-Year Retrospective Study of Uterine STUMP and Leiomyosarcoma
Previous Article in Journal
Does the Saudi Population Have Sufficient Awareness of Vitiligo in Southwest Saudi Arabia? A Cross-Sectional Survey, 2022
 
 
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Barriers and Facilitators to Conducting Oncology Clinical Trials in the UAE

by 1,2,3,4
1
Department of Oncology, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi P.O. Box 92510, United Arab Emirates
2
Innovation and Research Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi P.O. Box 92510, United Arab Emirates
3
College of Medicine, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates
4
Emirates Oncology Society, Dubai P.O. Box 6600, United Arab Emirates
Clin. Pract. 2022, 12(6), 885-896; https://doi.org/10.3390/clinpract12060093
Received: 1 September 2022 / Revised: 24 October 2022 / Accepted: 2 November 2022 / Published: 7 November 2022

Abstract

:
Cancer research and clinical trials are essential to improve cancer patients’ outcomes and advance the oncology field. The United Arab Emirates (UAE) has been lagging in cancer research with many barriers, including healthcare, institutional, regulatory, patient and community, the global oncology community, and the pharmaceutical industry. In this report, we try to address these challenges from our perspective. Making clinical trials accessible for cancer patients in the UAE requires a collaborative approach from all stakeholders and serious consideration for the greater cause to improve the patient’s outcome and contribute to the advancement of the cancer field worldwide. There has been significant support from the UAE government and the regulators in the UAE to facilitate and encourage research in general and cancer research in particular with recent initiatives and international collaborations. Private and public institutions must overcome their competitive moods and work together to strengthen the research network across the UAE and improve accrual for potential clinical trials. Public awareness and education must overcome long-standing perceptions about research and clinical trials in the UAE. The pharmaceutical industry must work closely with institutions across the UAE and support them in establishing accredited research programs and clinical trial units. The Emirates Oncology Society is establishing the Oncology Research Working Group to advocate and advance cancer research in the UAE. All stakeholders must be engaged to successfully implement impactful clinical trials in the UAE and the region.

1. Background

Between 1 January–31 December 2019, the total number of newly diagnosed cancer cases (malignant and in situ) reported to the United Arab Emirates National Cancer Registry (UAE-NCR) was 4633, of which 4381 (94.56%) were malignant and 252 (5.44%) were in situ cases. Overall, cancer was more prevalent among women than men; it affected 2604 (56.2%) females and 2029 (43.8%) males. Among UAE citizens, a total of 1193 cases were newly diagnosed with cancer, out of which 1117 (93.6%) were malignant and 76 (6.4%) were in situ cases. Similarly, in non-UAE citizens, 3440 cases were newly diagnosed with cancer, of which 3264 (94.9%) were malignant, and 176 (5.1%) were in situ cases, representing an overall crude incidence rate of 46.1/100,000 for both genders. There is a clear female predominance in cancer incidence. The crude incidence rate was higher for females (75.8/100,000) than for males (31.0/100,000). The overall age-standardized incidence rate (ASR) was 78.4/100,000. Breast, thyroid, colorectal, skin, and leukemia were the top-ranked cancers among all new cancer cases in both genders. Colorectal, skin, prostate, leukemia, and non-Hodgkin’s lymphoma were the top-ranked cancers among males. Among females, breast, thyroid, colorectal, uterus, and ovary were the top-ranked cancers. In the year 2019, there were 125 children in the age group of 0–14 years diagnosed with new cancer in the UAE (54% were females and 46% were males). This constitutes about 2.9% of all registered malignant cases. Leukemia, brain and CNS, connective and soft tissue, non-Hodgkin’s lymphoma, and bone and articular were the most common cancers in boys and girls. The third leading cause of death in the UAE, after diseases of the circulatory system and injuries, was found to be cancer. The number of deaths from cancer totaled 1181 (629 in males and 552 in females) and accounted for 13.11% of all deaths regardless of nationality, type of cancer, or gender. This represents an estimated age-standardized mortality rate of 33.3 deaths per 100,000 for both genders. Breast cancer was the leading cause of cancer death in 2019, with an estimated average of 11.6% of cancer deaths per year; colon cancer was the second most common cause of cancer death in both sexes, and lung cancer was the third most common cause of cancer death in both sexes [1].
Cancer care in the UAE has considerably evolved over the last two decades. However, advances in cancer research have notably lagged behind [2]. The USA and Europe are leading the cancer research world with significant research and development (R&D) programs; these programs have been long-established, well structured, and have received global recognition for their contribution to cancer research and improving patient outcomes. Oncology trials worldwide reached historically high levels in 2021, up 56% from 2016, and mostly focused on rare cancer indications [3,4]. No previous publications have addressed the barriers and facilitators to conducting cancer research in general and clinical trials in the United Arab Emirates (UAE). For perspective and to take breast cancer as an example, we conducted a dedicated and systematic literature search to identify publications related to breast cancer from the UAE. We searched PubMed using the terms “breast” AND “Cancer* OR Oncol* OR malignant* OR tumor OR tumor” AND “emirates OR UAE” on 8 August 2022. A total of 203 journal publications by authors from the UAE were retrieved, with the earliest publication being from 2001. The majority were basic science/translational (45.8%) or observational (26.1%) studies, while 40 (19.1%) were non-data-driven publications (e.g., reviews, consensus statements, editorials), and only five clinical trials were identified. Of note, among the 163 data-driven publications, only 62 (38%) were performed in the UAE, while the remaining were conducted abroad with authors having a UAE affiliation. Only seven clinical trials were identified by expanding the search to all cancers (Table 1).
We conducted a further search on clinicaltrials.gov to identify clinical trials that may not have been published; this search was done on 21 October 2022, and we identified 25 studies. There were 15 completed trials, 6 actively recruiting, and 3 of unknown status (Table 2).
Cancer research activities varied between the Gulf Cooperation Council Countries (UAE, Saudi Arabia, Oman, Bahrain, Qatar, and Kuwait). We conducted a search for oncology clinical trials in each country using clinicaltrials.gov. Saudi Arabia had the highest number of registered clinical trials with 175 trials, followed by the UAE with 25 registered clinical trials (Figure 1).
We herein provide perspectives on some of the reasons for such limited participation and conduct of clinical trials in the UAE while highlighting some unique opportunities.

2. Healthcare Provider Barriers

Healthcare providers are the cornerstone for clinical research; they identify the clinical question in their patient population that needs to be addressed in clinical trials and are responsible for the accrual of patients, the clinical assessment of treatment toxicity, and eventually the implementation of the clinical trial results in their patients. Many studies have assessed barriers to clinical research from healthcare providers’ perspectives. The following factors were identified: excessive clinical work, lack of personal motivation, lack of research experience, lack of research mentorship, lack of financial incentive, lack of protected time, and lack of understanding of the importance of research [12,13,14,15] (Figure 2). Most of these barriers related to healthcare providers in the UAE were also shared and highlighted in a survey to clarify UAE nurses’ perceptions of barriers to implementing research in clinical practice in the UAE. The two highest-ranked barriers to nurses conducting research in the UAE were a lack of time and competing demands for time [16] (Figure 2). Due to the lack of clear clinical oncology research programs in the UAE, skilled researchers and scholars are potentially migrating to Western countries for better opportunities; with more research programs, more opportunities will attract and retain researchers in the UAE and the wider region. Lastly, the medical school curriculum, residency, and fellowship training must include specific training and education for medical students and health care trainees to obtain research skills and experience.

3. Institutional Barriers

Institutions play a critical role in the ecosystem of oncology research and clinical trials. The lack of research programs and clinical trials units (CTUs) in health care institutions contributes immensely to the progress of cancer research in the UAE. Only a few cancer centers (5 out of 33) in the UAE have ongoing research and clinical trials. Establishing and activating such units is a limiting factor for cancer research. Lack of research leadership is another limitation. With the focus of institutions on meeting financial targets, less attention is given to clinical research. Furthermore, the competition between institutions may lead to poor collaboration between private institutions or between private and public institutions. To overcome this, institutions should see the value and potential of research networking and collaboration within the UAE (Figure 2). Lastly, the lack of promotion related to research productivity for clinicians must be evaluated and readdressed to increase the clinician’s interest and involvement.

4. Regulatory Barriers

In the UAE, multiple regulatory agencies exist (for the whole country and by Emirate), which means several approvals may need to be sought to conduct clinical research. In some instances, approvals may be lengthy or come with unpredictable approval timelines, although this is changing with the expansion of medical research teams in regulatory agencies and with optimized and more efficient procedures. The Dubai Health Authority, through the Dubai Scientific Research Ethics Committee (DSREC), follows the following general guidelines for research approvals in Dubai: Phase 1—not approved to be conducted in DHA; Phase 2—requires review and approval by higher management of the Dubai Health Authority; Phase 3 and Phase 4—DSREC review and a favorable opinion for the study submitted [17]. The Department of Health (DOH) in Abu Dhabi does allow the conduct of phases I and II trials in addition to phases III and IV [18,19]. The DOH has been leading research efforts at the regulatory level to enhance and improve the research capabilities in Abu Dhabi [20,21]. The Statistics and Research Center at the Ministry of Health and Prevention allows all types of clinical research with a more in-depth review before approval for phase I and II trials [22].

5. Patients and Community Barriers

With the lack of research and clinical trial culture in the medical community in the UAE, a lack of understanding of the importance of clinical trials is the norm among patients and the community. This leads to lower acceptance rates for enrollment in clinical trials, even if trials are accessible in the UAE. This is usually coupled with pre-existing wrong beliefs about clinical trials, e.g., fear of experimentation and trust issues. To change this, a strong awareness program about research/clinical trials is necessary (Figure 2).

6. Global Oncology Community Barriers

The global oncology community has an important role in supporting knowledge transfer and the involvement of researchers from the UAE and the region in designing and conducting clinical trials. However, the lack of trust in research capabilities in developing countries and the exclusion of researchers from those countries from research networks is another significant barrier. The lack of support for publications from developing countries in reputable journals is also a primary challenge [23]. The global community should continue to support and create mentorship programs and initiatives to support new research programs in the UAE and other countries (Figure 2).

7. Pharmaceutical Industry Barriers

Pharmaceutical research and development funding play a significant role in advancing cancer research and drug discovery [24]. The pharmaceutical industry’s support for research in some regions and countries, including the UAE, faces many challenges and barriers. This mainly stems from a lack of trust in research capabilities, concern about regulatory delays/processes, a limited/lack of accredited centers of excellence, and the absence of quality audits (local and international) of such centers. There is also a concern about successful accrual if clinical trials open in the UAE. The above challenges led to a lack of initiatives to support local research [18] and gaps in global vs. local pharmaceutical funding for research and investigator-initiated trials [25].

8. Conclusions

We have summarized barriers and potential facilitators for conducting oncology trials in the UAE, which may apply to other countries in the Middle East and Asia. There is a need for collaborative efforts from all stakeholders to address all these challenges. Efforts in cancer research are developing, although numerous evidence gaps remain. With the continuous growth in academic institutions and research programs committed to cellular and molecular research initiatives, the UAE’s scope for basic and translational research is typically improving. However, clinical research in general and clinical trials specifically are far from ideal in quantity and focus. There is an urgent need for a call to action from the local and global communities to optimize the inclusion of the UAE in international clinical trials and to provide local funding opportunities for local studies so that the efficacy and safety of drugs are evaluated in the local population rather than “assumed” from data from Western countries. The Emirates Oncology Society is establishing an oncology research group to advocate and advance cancer research in the UAE. For the success of this initiative, all stakeholders must support each other and work together for better cancer care in the UAE.

Funding

This research received support from Burjeel Medical City, Abu Dhabi, UAE.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Available online: https://mohap.gov.ae/assets/download/f3eb10c9/CANCER%20INCIDENCE%20IN%20UNITED%20ARAB%20EMIRATES%20ANNUAL%20REPORT%20OF%20THE%20UAE%20-%202019.pdf.aspx (accessed on 21 October 2022).
  2. Al-Shamsi, H.; Darr, H.; Abu-Gheida, I.; Ansari, J.; McManus, M.C.; Jaafar, H.; Tirmazy, S.H.; ElKhoury, M.; Azribi, F.; Jelovac, D.; et al. The State of Cancer Care in the United Arab Emirates in 2020: Challenges and Recommendations, A report by the United Arab Emirates Oncology Task Force. Gulf J. Oncol. 2020, 1, 71–87. [Google Scholar]
  3. Available online: https://www.iqvia.com/newsroom/2022/06/global-oncology-rd-surges-while-cancer-care-disruptions-ease-says-iqvia-institute-for-human-data-sci (accessed on 1 September 2022).
  4. Eckhouse, S.; Lewison, G.; Sullivan, R. Trends in the global funding and activity of cancer research. Mol. Oncol. 2008, 2, 20–32. [Google Scholar] [CrossRef] [PubMed]
  5. Ellis, M.; Zwaan, F.; Hedström, U.; Poynton, C.; Kristensen, J.; Jumaa, P.; Wassell, J.; al-Ramadi, B. Recombinant human interleukin 11 and bacterial infection in patients with [correction of] haematological malignant disease undergoing chemotherapy: A double-blind placebo-controlled randomised trial. Lancet 2003, 361, 275–280. [Google Scholar] [CrossRef]
  6. Ellis, M.; Hedstrom, U.; Frampton, C.; Alizadeh, H.; Kristensen, J.; Shammas, F.V.; Al-Ramadi, B.K. Modulation of the systemic inflammatory response by recombinant human interleukin-11: A prospective randomized placebo controlled clinical study in patients with hematological malignancy. Clin. Immunol. 2006, 120, 129–137. [Google Scholar] [CrossRef] [PubMed]
  7. Al-Tweigeri, T.; AlSayed, A.; Alawadi, S.; Ibrahim, M.; Ashour, W.; Jaafar, J.; Abulkhair, O.; Al-Abdulkarim, H.; Khalid, H.; Ajarim, D.; et al. A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin-docetaxel with or without trastuzumab in locally advanced breast cancer. Cancer Chemother. Pharm. 2016, 77, 147–153. [Google Scholar] [CrossRef] [PubMed]
  8. Gligorov, J.; Ataseven, B.; Verrillc, M.; De Laurentiis, M.; Jung, K.H.; Azim, H.A.; Al-Sakaff, N.; Lauer, S.; Shing, M.; Pivot, X. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study’s primary analysis of 2573 patients. Eur. J. Cancer 2017, 82, 237–246. [Google Scholar] [CrossRef] [PubMed]
  9. Tripathy, D.; Im, S.-A.; Colleoni, M.; Franke, F.; Bardia, A.; Harbeck, N.; Hurvitz, S.A.; Chow, L.; Sohn, J.; Lee, K.S.; et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A randomised phase 3 trial. Lancet Oncol. 2018, 19, 904–915. [Google Scholar] [CrossRef]
  10. Miles, D.; Ciruelos, E.; Schneeweiss, A.; Puglisi, F.; Peretz-Yablonski, T.; Campone, M.; Bondarenko, I.; Nowecki, Z.; Errihani, H.; Paluch-Shimon, S.; et al. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Ann. Oncol. 2021, 32, 1245–1255. [Google Scholar] [CrossRef] [PubMed]
  11. AlSaleh, K.; Al Zahwahry, H.; Bounedjar, A.; Oukkal, M.; Saadeddine, A.; Mahfouf, H.; Bouzid, K.; Bensalem, A.; Filali, T.; Abdel-Razeq, H.; et al. Response to Induction Neoadjuvant Hormonal Therapy Using Upfront 21-Gene Breast Recurrence Score Assay-Results from the SAFIA Phase III Trial. JCO Glob. Oncol. 2021, 7, 811–819. [Google Scholar] [CrossRef] [PubMed]
  12. Richardson, J.L.; Myrtle, R.; Solis, J.M.; Hisserich, J.W.; Oliver, D. Motivational factors for medical oncologists’ participation in cancer treatment protocols. J. Health Hum. Resour. Adm. 1986, 8, 212–230. [Google Scholar] [PubMed]
  13. Tirupakuzhi Vijayaraghavan, B.K.; Gupta, E.; Ramakrishnan, N.; Beane, A.; Haniffa, R.; Lone, N.; de Keizer, N.; Adhikari, N.K.J. Barriers and facilitators to the conduct of critical care research in low and lower-middle income countries: A scoping review. PLoS ONE 2022, 17, e0266836. [Google Scholar] [CrossRef] [PubMed]
  14. Alemayehu, C.; Mitchell, G.; Nikles, J. Barriers for conducting clinical trials in developing countries—A systematic review. Int. J. Equity Health 2018, 17, 37. [Google Scholar] [CrossRef] [PubMed]
  15. Khoja, A.; Kazim, F.; Ali, N.A. Barriers to Conducting Clinical Trials in Developing Countries. Ochsner J. 2019, 19, 294–295. [Google Scholar] [CrossRef]
  16. Al-Yateem, N.; Griffiths, J.; McCreaddie, M.; Robertson-Malt, S.; Kuzemski, D.; Anthony, J.M.; Fielding, M.; Al Khatib, F.; Sojka, E.M.; Williams, J.J. A National Scoping Study on Barriers to Conducting and Using Research Among Nurses in the United Arab Emirates. Policy Politics Nurs. Pract. 2019, 20, 216–227. [Google Scholar] [CrossRef]
  17. Available online: https://www.dha.gov.ae/en/MedicalEducationandResearch/MedicalResearch (accessed on 1 September 2022).
  18. Available online: https://doh.gov.ae/-/media/40B18D052C3E40B2A079ABD7571E2260.ashx (accessed on 1 September 2022).
  19. Available online: https://doh.gov.ae/-/media/C07A10ADB6504312A601E3A514D43084.ashx (accessed on 1 September 2022).
  20. Available online: https://www.zawya.com/en/world/middle-east/abu-dhabi-witnesses-launch-of-real-world-evidence-study-to-assess-astrazenecas-evusheld-o1p3b720 (accessed on 1 September 2022).
  21. Available online: https://www.arabianbusiness.com/industries/healthcare/abu-dhabi-department-of-health-inks-deal-to-develop-clinical-research-hub-innovative-treatments (accessed on 1 September 2022).
  22. Available online: https://mohap.gov.ae/en/services/request-for-support-and-coordination-of-medical-research (accessed on 1 September 2022).
  23. Hamadeh, R.R.; Jahrami, H.; Nazzal, K. Cancer Research in the Arab World. In Cancer in the Arab World; Al-Shamsi, H.O., Abu-Gheida, I.H., Iqbal, F., Al-Awadhi, A., Eds.; Springer: Singapore, 2022; pp. 395–408. [Google Scholar]
  24. Kanavos, P.; Sullivan, R.; Lewison, G.; Schurer, W.; Eckhouse, S.; Vlachopioti, Z. The role of funding and policies on innovation in cancer drug development. Ecancermedicalscience 2010, 4, 164. [Google Scholar] [CrossRef] [PubMed]
  25. Benhima, N.; El Fadli, M.; Essâdi, I.; Belbaraka, R. What does it take to conduct clinical trials in African countries? Insights from Morocco ecancer Ecancermedicalscience 2022, 16, 1411. [Google Scholar]
Figure 1. Registered clinical trials from the GCC countries at clinicaltrials.gov as of 21 October 2022.
Figure 1. Registered clinical trials from the GCC countries at clinicaltrials.gov as of 21 October 2022.
Clinpract 12 00093 g001
Figure 2. Barriers to oncology clinical trials in the UAE.
Figure 2. Barriers to oncology clinical trials in the UAE.
Clinpract 12 00093 g002
Table 1. Clinical trials in cancer indications conducted in the UAE. RCT, randomized, controlled trial.
Table 1. Clinical trials in cancer indications conducted in the UAE. RCT, randomized, controlled trial.
ReferenceYearCancerPhaseNumber of SubjectsArab Countries Participated
[5]2003Hematological malignancyIII40UAE only
[6]2006Hematological malignancyII20UAE only
[7]2016BreastII80Saudi Arabia, Kuwait, Egypt, UAE
[8]2017BreastIII2577Algeria, Egypt, Morocco, Saudi Arabia, UAE
[9]2018BreastIII672Lebanon, Saudi Arabia, UAE
[10]2021BreastIII1436Algeria, Egypt, Lebanon, Morocco, Saudi Arabia, UAE
[11]2021BreastIII258Algeria, Egypt, Jordan, Lebanon, Morocco, Saudi Arabia, Tunisia, UAE
Table 2. Clinical trials in the UAE registered at clinicaltrials.gov as of October 2022.
Table 2. Clinical trials in the UAE registered at clinicaltrials.gov as of October 2022.
TitleIdentifierConditionLocationStatusPhasePublication Indexed to Relevant NCT Number
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation (Pembro)NCT03879174Breast cancer—femaleMediclinic City Hospital, UAEUnknown222149876, 27959613, 24185512, 20479064
Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf Region (PREDICT)NCT03082976Ovarian cancerAl Ain, UAE (PI is from Tawam)CompletedN/A34930165
Epidemiological Study to Describe Non Small Cell Lung Cancer Clinical Management Patterns in MENA. Lung-EPICLIN/ Gulf (Lung-EPICLIN/G)NCT01562665Non-small cell lung cancerAl-Ain, Abu Dhabi (UAE)
PIs are from Zayed Military Hospital and Tawam Hospital)
CompletedN/AN/A
Retrospective Study to Describe the Real-world Treatment Patterns and Associated Clinical Outcomes in Patients With Metastatic Castration-resistant Prostates Cancer (REMPRO)NCT04801186Metastatic castration-resistant prostate cancerDubai and Abu Dhabi, UAERecruitingN/AN/A
Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East & North Africa (ALK NSCLC MENA)NCT02304406Non-small cell lung cancerTawam Hospital, Al-Ain/Al-Maqam (UAE) CompletedN/AN/A
Phase III Trial of High Dose vs. Standard Dose Vit D2 With Docetaxel in Met Breast ca (GORG-002)NCT00944424Breast cancerTawam Hospital, Al Ain, UAEUnknown3N/A
Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube Cancer (HALO)NCT04991051Fallopian tube cancerAl-Ain, UAECompletedN/AN/A
Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant (SAFIA)NCT03447132Breast neoplasm—femaleTawam Hospital, Al-Ain, UAECompleted3N/A
A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment NCT01702571Breast cancerUAECompleted334741021, 32634611
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (MONALEESA-7)NCT02278120Advanced metastatic breast cancerNovartis Investigative Site, Al Ain, UAEActive, not recruiting334965945, 34504990, 34158598, 33769862, 31305131, 31166679, 29804902
A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer (PERUSE)NCT01572038Breast neoplasmsTawam Hospital, Al-Ain, UAECompleted330796821
A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (SafeHER)NCT01566721Breast neoplasmsTawam Hospital, Al-Ain, UAECompleted330018134, 28625777
Chemotherapy Plus Surgery in Treating Children at Risk of or With Stage I Wilms’ TumorNCT00003804Kidney cancerTawam Hospital, UAEUnknown310463285, 19300220, 17084075, 15542800, 15175957, 20582946, 18811224, 22238153, 22513793, 21509706, 21370404, 21670612, 18095319, 17162067, 16410128
A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)NCT01351415Non-squamous, non-small cell lung cancerTawam Hospital, Al-Ain, UAECompleted330177994, 26828788, 21705281
AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung CancerNCT00961415Non-squamous, non-small cell lung cancerAl-Ain, UAECompleted323835708
Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer PatientsNCT00003938CancerTawam Hospital, UAECompleted3N/A
Prevention of Colorectal Cancer Through Multiomics Blood Testing (PREEMPT CRC)NCT04369053Colon cancer, rectal cancer, colon neoplasm, colon diseases, colon lesion, colon polyp, colorectal cancer, polyp, adenoma, rectal diseases, gastrointestinal tract cancersCleveland Clinic Abu Dhabi, Abu Dhabi, UAERecruitingN/AN/A
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice (IMreal)NCT03782207Urothelial carcinoma, non-small cell lung cancer, small cell lung cancer, hepatocellular carcinomaNMC Speciality Hospital, Abu Dhabi, UAE Tawam Hospital, Al-Ain, UAERecruitingN/AN/A
A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (TAIL)NCT03285763Carcinoma, non-small-cell lung cancerTawam Hospital, Al-Ain, UAECompleted433737339
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma (ELOQUENT-2)NCT01239797Lymphoma, multiple myelomaLocal Institution, Leicester, United Arab Emirates, LE1 5WWCompleted330204239, 28070715, 26035255
Prospective Urban Rural Epidemiology Study (PURE)NCT03225586Cardiovascular diseases, risk factor, cardiovascular, health behavior, environmental exposure, lung diseases, cancer, injuries, renal disease, communicable diseaseDubai Medical University, Dubai, UAERecruitingN/A36088949, 34261638, 32546275, 31965140, 30149823, 29734966
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients (ENESTxtnd)NCT01254188Chronic myeloid leukemiaNovartis Investigative Site, Dubai, UAECompleted328699641
An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib (ReAlec)NCT04764188NSCLCMediclinic Airport Road Hospital, Dubai, UAE Mediclinic City Hospital, Dubai, UAERecruitingN/AN/A
Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib (GIDEON)NCT00812175Carcinoma, hepatocellularMany locations, UAECompletedN/A29499662, 26901163, 20642705
Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin’s Lymphoma (iNHL) (NADIR)NCT02273856Indolent non-Hodgkin’s lymphoma (iNHL), chronic lymphocytic leukemia (CLL)Site AE97101 Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates, 51900Terminated (The study was terminated due to insufficient subject enrollment and very slow enrollment.)N/AN/A
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Al-Shamsi, H.O. Barriers and Facilitators to Conducting Oncology Clinical Trials in the UAE. Clin. Pract. 2022, 12, 885-896. https://doi.org/10.3390/clinpract12060093

AMA Style

Al-Shamsi HO. Barriers and Facilitators to Conducting Oncology Clinical Trials in the UAE. Clinics and Practice. 2022; 12(6):885-896. https://doi.org/10.3390/clinpract12060093

Chicago/Turabian Style

Al-Shamsi, Humaid O. 2022. "Barriers and Facilitators to Conducting Oncology Clinical Trials in the UAE" Clinics and Practice 12, no. 6: 885-896. https://doi.org/10.3390/clinpract12060093

Article Metrics

Back to TopTop